EUDA

424B3 - EUDA Health Holdings Ltd (0001847846) (Filer)

EFFECT - EUDA Health Holdings Ltd (0001847846) (Filer)

F-3/A - EUDA Health Holdings Ltd (0001847846) (Filer)

6-K - EUDA Health Holdings Ltd (0001847846) (Filer)

SINGAPORE, July 30, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ:EUDA) a Singapore-based distributor of third-party provided wellness and non-invasive healthcare products and services in Asia, with a focus on Singapore, Malaysia and China, today provided important additional details of the integrated cell therapy program to be pursued under its recently announced non-binding Memorandum of Understanding (MOU) with GO POSB Organoids Pte Ltd ("GO POSB") and Shenzhen Innovation Immunotechnology Co., Ltd. ("SIIT"). Subject to the execution of definitive agreements and applicable regulatory approvals, parties plan to combine GO POSB’s proprietary induced pluripotent stem cell (

6-K - EUDA Health Holdings Ltd (0001847846) (Filer)

SINGAPORE, July 28, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ:EUDA) a Singapore-based distributor of third-party provided wellness and non-invasive healthcare products and services in Asia, with a focus on Singapore, Malaysia and China, today announced that it has signed a Memorandum of Understanding ("MOU") with GO POSB Organoids Pte Ltd ("GO POSB") and Shenzhen Innovation Immunotechnology Co., Ltd. ("SIIT") to establish a tri-party collaboration with next-generation therapies derived from induced pluripotent stem cells ("iPSC"). The MOU details the parties intentions to collaborate on the development, manufacturing and commercialization of a first of its kind next  g

424B5 - EUDA Health Holdings Ltd (0001847846) (Filer)

F-3/A - EUDA Health Holdings Ltd (0001847846) (Filer)

F-3/A - EUDA Health Holdings Ltd (0001847846) (Filer)

424B5 - EUDA Health Holdings Ltd (0001847846) (Filer)

6-K - EUDA Health Holdings Ltd (0001847846) (Filer)

SCHEDULE 13G/A - EUDA Health Holdings Ltd (0001847846) (Subject)

6-K - EUDA Health Holdings Ltd (0001847846) (Filer)

6-K - EUDA Health Holdings Ltd (0001847846) (Filer)

SINGAPORE, June 01, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ:EUDA) ("EUDA" or the "Company"), a Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia and China, today announced it is expanding the Helixé product line with the launch of the Regenixé iPSC-derived Skin Stem Cell Secretome Mask ("Regenixé Mask"), a beauty product developed by Chemokine Pte Ltd ("Chemokine"). EUDA holds the exclusive global distributorship rights for Helixé products, that includes but is not limited to, a next-generation immune health supplement, from Chemokine, a Singapore-based biotech company focused on molecular supplements and gene-modulating fo

Singapore, June 01, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited ("EUDA" and the "Company"), a Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia and China, received a written notice (the "MVLS Notice") from Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") on April 23, 2026, indicating that the Company had failed to maintain a Minimum Market Value of Listed Securities ("MVLS") of $35 million over the last 32 consecutive business days as required by the Nasdaq Listing Rule 5550(b)(2). On May 28, 2026, the Company received a written notice from Nasdaq stating that the Company's Market Value of Listed Securities has b

F-3 - EUDA Health Holdings Ltd (0001847846) (Filer)

6-K - EUDA Health Holdings Ltd (0001847846) (Filer)

20-F - EUDA Health Holdings Ltd (0001847846) (Filer)

SINGAPORE, April 28, 2026 (GLOBE NEWSWIRE) --  EUDA Health Holdings Limited (NASDAQ:EUDA) ("EUDA" or the "Company"), a Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia and China, today announced that Shenzhen Inno Immune Co., Ltd. ("Shenzhen Inno"), a developer of cellular therapies in China, has received official approval under the 2025 Shenzhen Key Industry R&D Program. The Shenzhen Key Industry R&D Program is a government-run initiative designed to support critical technological innovation and industrial development. The approved project is scheduled to be implemented from January 1, 2026, to December 31, 2028, under the supervision of the Sh

6-K - EUDA Health Holdings Ltd (0001847846) (Filer)

Singapore, April 27, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited ("EUDA" and the "Company") received a written notice (the "MVLS Notice") from Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") on April 23, 2026, indicating that the Company had failed to maintain a Minimum Market Value of Listed Securities ("MVLS") of $35 million over the last 32 consecutive business days as required by the Nasdaq Listing Rule 5550(b)(2). The MVLS Notice has no immediate effect on the listing of the Company's securities on Nasdaq and the Company has been provided a period of 180 calendar days from the date of the MVLS Notice, or until October 20, 2026, in which to regain co

6-K - EUDA Health Holdings Ltd (0001847846) (Filer)

SINGAPORE, March 19, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ:EUDA) ("EUDA" or the "Company"), a Singapore based non-invasive healthcare provider in Asia focused on Singapore, Malaysia and China, today announced that it will implement a reverse stock split of its ordinary shares at a ratio of 1-for-20 (the "Reverse Stock Split"). The Reverse Stock Split was approved by the Company's Board of Directors in accordance with British Virgin Islands law. The Reverse Stock Split will take effect at market open on March 23, 2026, and the ordinary shares will trade on a post-split basis on the Nasdaq Capital Market under the Company's existing trading symbol "EUDA" and will con